- Home
- DTF vs TCRX Comparison
DTF vs TCRX Comparison
Compare DTF & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTF
- TCRX
- Stock Information
- Founded
- DTF 1991
- TCRX 2018
- Country
- DTF United States
- TCRX United States
- Employees
- DTF N/A
- TCRX N/A
- Industry
- DTF Investment Managers
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- DTF Finance
- TCRX Health Care
- Exchange
- DTF Nasdaq
- TCRX Nasdaq
- Market Cap
- DTF 78.2M
- TCRX 90.5M
- IPO Year
- DTF N/A
- TCRX 2021
- Fundamental
- Price
- DTF $11.19
- TCRX $1.75
- Analyst Decision
- DTF
- TCRX Strong Buy
- Analyst Count
- DTF 0
- TCRX 6
- Target Price
- DTF N/A
- TCRX $9.50
- AVG Volume (30 Days)
- DTF 21.1K
- TCRX 833.5K
- Earning Date
- DTF 01-01-0001
- TCRX 05-06-2025
- Dividend Yield
- DTF 3.64%
- TCRX N/A
- EPS Growth
- DTF N/A
- TCRX N/A
- EPS
- DTF 0.44
- TCRX N/A
- Revenue
- DTF N/A
- TCRX $4,421,000.00
- Revenue This Year
- DTF N/A
- TCRX $68.86
- Revenue Next Year
- DTF N/A
- TCRX $14.01
- P/E Ratio
- DTF $24.34
- TCRX N/A
- Revenue Growth
- DTF N/A
- TCRX N/A
- 52 Week Low
- DTF $10.29
- TCRX $1.02
- 52 Week High
- DTF $11.19
- TCRX $9.29
- Technical
- Relative Strength Index (RSI)
- DTF 52.43
- TCRX 67.20
- Support Level
- DTF $11.14
- TCRX $1.39
- Resistance Level
- DTF $11.21
- TCRX $1.49
- Average True Range (ATR)
- DTF 0.05
- TCRX 0.12
- MACD
- DTF 0.00
- TCRX 0.04
- Stochastic Oscillator
- DTF 55.00
- TCRX 100.00
About DTF DTF Tax-Free Income 2028 Term Fund Inc.
DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing primarily in a diversified portfolio of investment-grade tax-exempt obligations.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.